Case study 1: 63-year-old male
Case study 1 looks at a 63-year-old male patient with high-risk AML and discusses the importance of early diagnosis, as well as the benefits of rapid initiation with Defitelio® treatment.
Case studies Diagnosis and severity grading Risk assessment and monitoring
ADVERSE EVENTS REPORTING
Adverse events should be reported. Reporting forms and information for the UK can be found at: https://yellowcard.mhra.gov.uk/
For Ireland, reporting forms and information can be found at: www.hpra.ie
Adverse events should also be reported to Jazz Pharmaceuticals at: AEreporting@jazzpharma.com
Defitelio® is indicated for the treatment of severe hepatic veno-occlusive disease (VOD) also known as sinusoidal obstruction syndrome (SOS) in haematopoietic stem-cell transplantation (HSCT) therapy. It is indicated in adults and in adolescents, children and infants over 1 month of age.